Page last updated: 2024-11-12

gentamicin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gentamicin B: RN given refers to gentamicin B; see also records for gentamicin A and gentamicin C [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11754987
CHEMBL ID2110604
SCHEMBL ID509198
MeSH IDM0081453

Synonyms (24)

Synonym
betamicina [inn-spanish]
gentamicin b
betamicine [inn-french]
d-streptamine, o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy-
betamicinum [inn-latin]
betamicin [inn]
betamicin
gentamycin b
o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy-d-streptamine
betamicine
unii-67w9dgg4c7
betamicinum
betamicina
67w9dgg4c7 ,
36889-15-3
d-streptamine, o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy-
sch-14342
SCHEMBL509198
RHRAMPXHWHSKQB-GGEUKFTFSA-N
CHEMBL2110604
(2r,3s,4s,5r,6r)-2-(aminomethyl)-6-((1r,2r,3s,4r,6s)-4,6-diamino-3-((2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2h-pyran-2-yloxy)-2-hydroxycyclohexyloxy)tetrahydro-2h-pyran-3,4,5-triol
(2r,3s,4s,5r,6r)-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-3-[(2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
Q27264175
DTXSID101043341

Research Excerpts

Overview

Gentamicin B is a naturally occurring minor component isolated from Micromonospora echinospora.

ExcerptReferenceRelevance
"Gentamicin B is a naturally occurring minor component isolated from Micromonospora echinospora."( Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora.
Cui, H; Gu, Y; Ni, X; Sun, Z; Xia, H, 2016
)
1.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1586839Induction of read through activity at cricket paralysis virus-internal ribosome entry site premature termination codon UGA assessed as ratio of plateau octapeptide to FKVRQ-tRNAGln measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S]-Met-tRN2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID1586838Induction of read through activity at cricket paralysis virus-internal ribosome entry site premature termination codon UGA assessed as increase in octapeptide formation from FKVRQ-tRNAGln measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S]-2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID1586840Induction of read through activity at cricket paralysis virus-internal ribosome entry site codon UGG assessed as increase in octapeptide formation from FKVRQ-tRNAGln at EC50 to 2 times EC50 measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.36 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index26.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]